Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

Table 2

Sensitivity analysis for all studies versus those studies with score of ≥2.

Outcomes	Meta-analysis for all studies				Meta-analysis for those studies with score of ≥2
	Number	Total patients; (intervention/control groups)	RR (95% CI)	value	Number	Total patients; (intervention/control groups)	RR (95% CI)	value
6-month SR	5	422 (213/209)	1.58 (1.05, 2.37)	0.03	4	289 (145/141)	1.63 (0.94, 2.83)	0.08
1-year SR	8	579 (297/282)	1.85 (1.49, 2.31)	0.00001	5	298 (150/148)	1.82 (1.33, 2.49)	0.0002
ORR	25	1498 (773, 725)	1.42 (1.26, 1.59)	0.00001	16	873 (440/433)	1.54 (1.31, 1.80)	0.00001
DCR	23	1367 (706, 661)	1.25 (1.12, 1.39)	0.0001	15	797 (401/396)	1.23 (1.10, 1.37)	0.0003
Gastrointestinal reaction	7	420 (211/209)	1.55 (1.30, 1.84)	0.00001	6	302 (154/148)	0.36 (0.17, 0.73)	0.005
Leukopenia of grades III-IV	10	654 (339/315)	0.71 (0.57, 0.90)	0.004	5	322 (163/159)	0.68 (0.29, 1.58)	0.36
Leukopenia of grades I–IV	8	505 (253/252)	0.74 (0.55/0.99)	0.05	5	324 (164/160)	0.72 (0.45, 1.15)	0.17
Thrombocytopenia of grades I–IV	7	420 (210/210)	0.74 (0.47, 1.18)	0.21	5	303 (153/150)	0.80 (0.48, 1.32)	0.38